Similar 5-year HCC occurrence in Tenofovir- and Entecavir-treated HBV chronic infection in the French AFEF/ANRS CO22 Hepather cohort.
Archive ouverte
Pol, Stanislas | Bonnet, Delphine | Payssan-Sicart, Virginie | Pomes, Chloe | Bailly, François | Beaudoin, Marjolaine | Giboz, Dominique | Hartig-Lavie, Kerstin | Maynard, Marianne | Billaud, Eric | Boutoille, David | Cavellec, Morane | Chevalier, Caroline | Hubert, Isabelle | Goepfert, Pierre | Lannes, Adrien | Lunel, François | Boursier, Jérôme | Boyer, Nathalie | Giuily, Nathalie | Castelnau, Corinne | Scoazec, Giovanna | Chibah, Aziza | Keser, Sylvie | Bonardi, Karim | Vallet-Pichard, Anaïs | Sogni, Philippe | Foucher, Juliette | Hiriart, Jean-Baptiste | Legendre, Amandine | Chermak, Faiza | Irlès-Depé, Marie | Ahmed, Si Nafa Si | Ansaldi, Christelle | Amara, Nisserine Ben | Oules, Valérie | Dunette, Jacqueline | Anty, Rodolphe | Gelsi, Eve | Truchi, Régin | Luckina, Elena | Messaoudi, Nadia | Moussali, Joseph | Dieuleveult, Barbara De | Goin, Héloïse | Labarrière, Damien | Potier, Pascal | Grando-Lemaire, Véronique | Nahon, Pierre | Brulé, Séverin | Monard, Rym | Jezequel, Caroline | Brener, Audrey | Laligant, Anne | Rabot, Aline | Renard, Isabelle | Baumert, Thomas F | Dofföel, Michel | Mutter, Catherine | Simo-Noumbissie, Pauline | Razi, Esma | Barraud, Hélène | Bensenane, Mouni | Nani, Abdelbasset | Hassani-Nani, Sarah | Bernard, Marie-Albertine | Pageaux, Georges-Philippe | Bismuth, Michael | Caillo, Ludovic | Faure, Stéphani | Ripault, Marie Pierre | Bureau, Christophe | Launay, Sarah | Peron, Jean Marie | Robic, Marie Angèl | Tarallo, Lé | Faure, Marine | Froissart, Bruno | Hilleret, Marie-Noelle | Zarski, Jean-Pierre | Goria, Odile | Grard, Victorien | E Montialoux, Hélè | François, Muriel | Ouedraogo, Christian | Pauleau, Christelle | Varault, Anne | Andreani, Tony | E Angoulevant, Bénédic | Chevance, Azeline | Serfaty, Lawrence | Antonini, Teresa | Coilly, Audrey | Vallée, Jean-Charles Duclos | Tateo, Mariagrazia | Bonny, Corinne | Brigitte, Chanteranne | Lamblin, Géraldin | Muti, Léo | Babouri, Abdenour | Filipe, Virginie | Barrault, Camille | Costes, Laurent | Merbah, Soraya | Carrier, Paul | Debette-Gratien, Maryline | Jacques, Jérémie | Lassailly, Guillaume | Artu, Florent | Canva, Valérie | Dharancy, Sébastie | Louvet, Alexandre | Latournerie, Marianne | Bardou, Marc | Mouillot, Thomas | Bacq, Yannick | Barbereau, Didier | Nicolas, Charlotte | Archambeaud, Isabelle | Habes, Sarah | Botta-Fridlund, Danièl | Saillard, Eric | Lafrance, Marie-José | Nzinga, Clovis Luzivika | Dorival, Céline | Zoulim, Fabien | Cagnot, Carole | Decaens, Thomas | Thabut, Dominique | Asselah, Tarik | Mathurin, Philippe | Ganne, Nathalie | Samuel, Didier | Habersetzer, Françoi | Bronowicki, Jean-Pierre | Guyader, Dominique | Rosa, Isabelle | Leroy, Vincent | Chazouilleres, Olivier | Ledinghen, Victor De | Bourliere, Marc | Causse, Xavier | Cales, Paul | Metivier, Sophie | Loustaud-Ratti, Véroniqu | Abergel, Armand | Fontaine, Hélène | Carrat, Fabrice
Edité par
CCSD -
International audience.
Background: Chronic hepatitis B virus (HBV) infection results in a high risk of cirrhosis and its complications, cirrhosis decompensation (DC), hepatocellular carcinoma (HCC), liver transplantation (LT), death or any of these outcomes (composite endpoint [CE]). Nucleos(t)ide analogues (NUCs) such as tenofovir or entecavir are associated with a reduction in these complications.Aim: To compare the impact of tenofovir and entecavir on these outcomes in patients treated for HBV infection and included in the prospective Hepather cohort.Methods: All patients with HBV infection who had received tenofovir or entecavir for more than 6 months at or after entry in the ANRS CO22 cohort were selected. Patients with HDV and HCV co-infection or prior liver event were excluded. Incidence rates of events were compared using inverse probability of treatment weighting (IPW).Results: The cohort included 1800 patients (986 tenofovir and 814 entecavir). Median follow-up was 4.2 years. The incidences of HCC, DC, LT, ACD, LRD and CE were not different between tenofovir- (1.8 (0.9; 3.2), 0.6 (0.2; 1.6), 0.2 (0.0; 0.8), 1.7 (0.8; 3.0), 0.8 (0.2, 1.8) and 4.1 (3.0; 5.4) per 1000 person-years) and entecavir-treated patients (1.6 (0.7; 3.0), 0.7 (0.2; 1.8), 0.2 (0.0; 1.0), 3.0 (1.7, 4.8), 0.5 (0.1; 1.5) and 5.0 (3.3; 7.2)) per 1000 person-years, respectively.Conclusion: The risk of liver-related events or death was not different between tenofovir- and entecavir-treated patients in this large prospective cohort of predominantly non-cirrhotic French patients.Trial registration number: NCT019553458.
